Hydroxychloroquine Maintenance Associated With Lower Flare Risk in Patients With SLE
>
>
Hydroxychloroquine Maintenance Associated With Lower Flare Risk in Patients With SLE

Hydroxychloroquine Maintenance Associated With Lower Flare Risk in Patients With SLE

In patients with systemic lupus erythematosus (SLE), reduction or discontinuation of hydroxychloroquine (HCQ) is associated with a 2-fold increased risk for flares, even during remission.

Flare risk was found to be higher with HCQ reduction (HR, 1.13; 95% CI, 0.98-1.30) and discontinuation (HR, 1.41; 95% CI, 1.19-1.67) compared with HCQ maintenance.

Estimated reasons for HCQ reduction included American Academy of Ophthalmology guidelines (5%) and low disease activity (55%). Reasons for HCQ discontinuation included retinal changes (4%) and clinical remission (15%). The remainder of patients in each cohort reduced or discontinued HCQ for other reasons, including intolerance or patient preference

Read More: Brasil C, Hanly J, Urowitz M, et al. Impact of systemic lupus disease activity state on flare risk after hydroxychloroquine maintenance, reduction or discontinuation in a multinational inception cohort. Presented at: ACR Convergence 2021; November 3-10, 2021. Abstract 0959

Share on

There are no comments

Leave a Reply

Your email address will not be published. Required fields are marked *

Start typing and press Enter to search

Shopping Cart